-
公开(公告)号：US20190030004A1
公开(公告)日：2019-01-31
申请号：US16023102
申请日：2018-06-29
Applicant: AstraZeneca AB , Array BioPharma, Inc.
Inventor： Nicola Frances BATEMAN , Paul Richard GELLERT , Kathryn Jane HILL
IPC: A61K31/4184 , C07D235/06 , A61K9/14 , A61K9/48 , A61K47/36 , A61K9/00 , A61K47/22
Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2019/01/08/US10174028B2/abs.jpg.150x150.jpg)
公开(公告)号：US10174028B2
公开(公告)日：2019-01-08
申请号：US15860849
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , James F. Blake , Mark J. Chicarelli , Adam Golos , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski
IPC: C07D471/04 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/499 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D519/00
Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2018/12/04/US10144734B2/abs.jpg.150x150.jpg)
公开(公告)号：US10144734B2
公开(公告)日：2018-12-04
申请号：US15858929
申请日：2017-12-29
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: C07D471/04 , A61K31/4162 , A61P1/00 , A61P35/00
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors](/abs-image/US/2018/11/27/US10137124B2/abs.jpg.150x150.jpg)
公开(公告)号：US10137124B2
公开(公告)日：2018-11-27
申请号：US15860852
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/437 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号：US20180297986A1
公开(公告)日：2018-10-18
申请号：US15818264
申请日：2017-11-20
Applicant: Array BioPharma, Inc.
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: C07D403/04 , A61K31/4184 , A61K9/00 , C07D405/14 , C07D401/14 , A61K45/06 , A61K31/506
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
Patent Agency Ranking
公开(公告)号：US20180296533A1
公开(公告)日：2018-10-18
申请号：US15842715
申请日：2017-12-14
Applicant: Array BioPharma Inc.
Inventor： Christoph Max Krell , Marian Misun , Daniel Andreas Niederer , Werner Heinz Pachinger , Marie-Christine Wolf , Daniel Zimmermann , Weidong Liu , Peter J. Stengel , Paul Nichols
IPC: A61K31/4184 , A61K45/06 , A61K47/26 , A61K9/20 , A61K9/00 , C07D235/08 , C07D235/06 , A61K47/12 , A61K47/02 , C30B29/54 , C30B7/08 , A61K47/38
CPC classification number: A61K31/4184 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K45/06 , A61K47/02 , A61K47/12 , A61K47/26 , A61K47/38 , C07B2200/13 , C07D235/06 , C07D235/08 , C30B7/08 , C30B29/54
Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/07/05/US20180186790A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180186790A1
公开(公告)日：2018-07-05
申请号：US15858658
申请日：2017-12-29
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , James F. Blake , Mark J. Chicarelli , Adam Golos , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski
IPC: C07D471/04 , A61K31/55 , A61K45/06 , A61K31/499 , A61K31/444 , A61K31/5377 , A61K31/496 , A61K31/497 , C07D519/00 , A61K31/506 , A61K31/4545
CPC classification number: C07D471/04 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/499 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D519/00
Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
-
![Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds](/abs-image/US/2018/06/26/US10005783B2/abs.jpg.150x150.jpg)
公开(公告)号：US10005783B2
公开(公告)日：2018-06-26
申请号：US15399389
申请日：2017-01-05
Applicant: Array BioPharma, Inc.
Inventor： Julia Haas , Steven W. Andrews , Yutong Jiang , Gan Zhang
IPC: C07D487/04 , C07D519/00 , C07D471/04 , A61K45/06 , A61K31/5377 , A61K31/519 , A61K9/00
CPC classification number: C07D487/04 , A61K9/0053 , A61K31/519 , A61K31/5377 , A61K45/06 , A61P29/00 , C07D471/04 , C07D519/00 , Y02A50/414
Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
-
39.发明申请公开(公告)号：US20180169099A1
公开(公告)日：2018-06-21
申请号：US15670874
申请日：2017-08-07
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： Ian S. Mitchell , James F. Blake , Rui Xu , Nicholas C. Kallan , Dengming Xiao , Keith Lee Spencer , Josef R. Bencsik , Eli M. Wallace , Stephen T. Schlachter , Anna L. Leivers , Jun Liang , Brian Safina , Birong Zhang , Christine Chabot , Steven Do
IPC: A61K31/517 , C07D413/12 , C07D409/14 , C07D409/12 , C07D239/70 , C07D405/12 , C07D403/12 , C07D401/12 , C07D407/12
CPC classification number: A61K31/517 , C07D239/70 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12
Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/05/17/US20180133200A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180133200A1
公开(公告)日：2018-05-17
申请号：US15860852
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/444 , A61K31/496 , A61P35/00 , A61P35/02 , A61K45/06 , A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/551
CPC classification number: C07D471/04 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
-
-
-
-
-
-
-
-
Search Results
435
records
(took 0.081 seconds)
